Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Delayed Quote USD

Galectin Therapeutics Inc. (GALT)

1.3400
+0.0100
+(0.75%)
At close: April 23 at 4:00:01 PM EDT
1.3995
+0.06
+(4.44%)
After hours: April 23 at 7:30:50 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
42,433
42,433
38,072
38,352
30,179
Operating Income
-42,433
-42,433
-38,072
-38,352
-30,179
Net Non Operating Interest Income Expense
-5,202
-5,202
-2,562
-981
-486
Other Income Expense
588
588
-432
557
138
Pretax Income
-47,047
-47,047
-41,066
-38,776
-30,527
Net Income Common Stockholders
-47,200
-47,200
-44,805
-38,873
-30,698
Diluted NI Available to Com Stockholders
-47,200
-47,200
-44,805
-38,873
-30,698
Basic EPS
-0.76
-0.76
-0.74
-0.65
-0.52
Diluted EPS
-0.76
-0.76
-0.74
-0.65
-0.52
Basic Average Shares
62,309
62,309
60,159
59,391
58,527
Diluted Average Shares
62,309
62,309
60,159
59,391
58,527
Total Operating Income as Reported
-42,433
-42,433
-38,072
-38,352
-30,179
Total Expenses
42,433
42,433
38,072
38,352
30,179
Net Income from Continuing & Discontinued Operation
-47,047
-47,047
-41,066
-38,776
-30,527
Normalized Income
-47,635
-47,635
-40,634
-39,333
-30,665
Interest Income
338
338
230
52
3
Interest Expense
5,540
5,540
2,792
1,033
489
Net Interest Income
-5,202
-5,202
-2,562
-981
-486
EBIT
-41,507
-41,507
-38,274
-37,743
-30,038
EBITDA
-41,470
-41,470
-38,241
-37,711
-29,997
Reconciled Depreciation
37
37
33
32
41
Net Income from Continuing Operation Net Minority Interest
-47,047
-47,047
-41,066
-38,776
-30,527
Total Unusual Items Excluding Goodwill
588
588
-432
557
138
Total Unusual Items
588
588
-432
557
138
Normalized EBITDA
-42,058
-42,058
-37,809
-38,268
-30,135
12/31/2021 - 9/4/2002

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BIXT Bioxytran, Inc.
0.1650
+2.68%
 
GLTO Galecto, Inc.
2.7500
+2.61%
 
IKT Inhibikase Therapeutics, Inc.
2.1600
+10.20%
 
LCTX Lineage Cell Therapeutics, Inc.
0.4720
+9.82%
 
AUPH Aurinia Pharmaceuticals Inc.
8.09
+2.53%
 
GRCE Grace Therapeutics, Inc.
2.3000
+0.44%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.3030
+4.48%
 
SLS SELLAS Life Sciences Group, Inc.
1.3100
+1.55%
 
NRIX Nurix Therapeutics, Inc.
11.61
+1.31%
 
TCBPY TC Biopharm (Holdings) Plc
0.4500
+45.16%